{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T07:20:23Z","timestamp":1766647223201,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008441","name":"CYTED","doi-asserted-by":"publisher","award":["network RIIDFCM"],"award-info":[{"award-number":["network RIIDFCM"]}],"id":[{"id":"10.13039\/501100008441","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia \u2013 F.C.T.","award":["PEst-OE\/QUI\/UI0100\/2011, PEst-OE\/QUI\/UI0612\/2011, PEst-OE\/QUI\/UI0536\/2011, UID\/QUI\/00100\/2019"],"award-info":[{"award-number":["PEst-OE\/QUI\/UI0100\/2011, PEst-OE\/QUI\/UI0612\/2011, PEst-OE\/QUI\/UI0536\/2011, UID\/QUI\/00100\/2019"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia \u2013 F.C.T","award":["projects PTDC\/QuiQui\/101187 \/2008, PTDC\/BBB-BQB\/6071\/2014 and IF\/01179\/2013"],"award-info":[{"award-number":["projects PTDC\/QuiQui\/101187 \/2008, PTDC\/BBB-BQB\/6071\/2014 and IF\/01179\/2013"]}]},{"name":"POPH","award":["(Programa Operacional para o Potencial Humano)"],"award-info":[{"award-number":["(Programa Operacional para o Potencial Humano)"]}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["Investigador 2013 Initiative"],"award-info":[{"award-number":["Investigador 2013 Initiative"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The steady rise in the cancer burden and grim statistics set a vital need for new therapeutic solutions. Given their high efficiency, metallodrugs are quite appealing in cancer chemotherapy. This work examined the anticancer activity of an anti-trypanosomal ruthenium-based compound bearing the 5-nitrofuryl pharmacophore, [RuII(dmso)2(5-nitro-2-furaldehyde semicarbazone)] (abbreviated as RuNTF; dmso is the dimethyl sulfoxide ligand). The cytotoxicity of RuNTF was evaluated in vitro against ovarian adenocarcinoma, hormone-dependent breast adenocarcinoma, prostate carcinoma (grade IV) and V79 lung fibroblasts human cells. The activity of RuNTF was similar to the benchmark metallodrug cisplatin for the breast line and inactive against the prostate line and lung fibroblasts. Given the known role of serum protein binding in drug bioavailability and the distribution via blood plasma, this study assessed the interaction of RuNTF with human serum albumin (HSA) by circular dichroism (CD) and fluorescence spectroscopy. The fluorescence emission quenching from the HSA-Trp214 residue and the lifetime data upon RuNTF binding evidenced the formation of a 1:1 {RuNTF-albumin} adduct with log Ksv = (4.58 \u00b1 0.01) and log KB = (4.55 \u00b1 0.01). This is supported by CD data with an induced CD broad band observed at ~450 nm even after short incubation times. Importantly, the binding to either HSA or human apo-transferrin is beneficial to the cytotoxicity of the complex towards human cancer cells by enhancing the cytotoxic activity of RuNTF.<\/jats:p>","DOI":"10.3390\/molecules24162861","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T10:56:38Z","timestamp":1565175398000},"page":"2861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity"],"prefix":"10.3390","volume":"24","author":[{"given":"Bruno","family":"Demoro","sequence":"first","affiliation":[{"name":"C\u00e1tedra de Qu\u00edmica Inorg\u00e1nica, Facultad de Qu\u00edmica, Universidad de la Rep\u00fablica\u2014UDELAR, 11800 Montevideo, Uruguay"}]},{"given":"Andreia","family":"Bento-Oliveira","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias\u2014CQE-FCUL, Universidade de Lisboa, 1749-016 Lisbon, Portugal"},{"name":"Centro de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias da Universidade de Lisboa, 1749-016 Lisbon, Portugal"}]},{"given":"Fernanda","family":"Marques","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias Tecnol\u00f3gicas e Nucleares, Instituto Superior T\u00e9cnico\u2014C2TN-T\u00e9cnico, Universidade de Lisboa, Campus Tecnol\u00f3gico e Nuclear, 2686-953 Sacav\u00e9m, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-9964","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Costa Pessoa","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Departamento de Engenharia Qu\u00edmica, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal"}]},{"given":"Luc\u00eda","family":"Otero","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Qu\u00edmica Inorg\u00e1nica, Facultad de Qu\u00edmica, Universidad de la Rep\u00fablica\u2014UDELAR, 11800 Montevideo, Uruguay"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-7374","authenticated-orcid":false,"given":"Dinorah","family":"Gambino","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Qu\u00edmica Inorg\u00e1nica, Facultad de Qu\u00edmica, Universidad de la Rep\u00fablica\u2014UDELAR, 11800 Montevideo, Uruguay"}]},{"given":"Rodrigo","family":"F. M. de Almeida","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias\u2014CQE-FCUL, Universidade de Lisboa, 1749-016 Lisbon, Portugal"},{"name":"Centro de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias da Universidade de Lisboa, 1749-016 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2249-4684","authenticated-orcid":false,"given":"Ana Isabel","family":"Tomaz","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias\u2014CQE-FCUL, Universidade de Lisboa, 1749-016 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"ref_1","unstructured":"(2019, July 09). Cancer. Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_2","unstructured":"(2019, July 09). Global Cancer Observatory. Available online: https:\/\/gco.iarc.fr\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","article-title":"Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?","volume":"119","author":"Kenny","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2017.11.014","article-title":"Platinum coordination compounds with potent anticancer activity","volume":"375","author":"Deo","year":"2018","journal-title":"Coord. Chem. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jinorgbio.2011.09.030","article-title":"Approaching tumour therapy beyond platinum drugs","volume":"106","author":"Bergamo","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jakupec, M.A., Galanski, M., Arion, V.B., Hartinger, C.G., and Keppler, B.K. (2008). Antitumour metal compounds: More than theme and variations. Dalton Trans., 183\u2013194.","DOI":"10.1039\/B712656P"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dyson, P.J., and Sava, G. (2006). Metal-based antitumour drugs in the post genomic era. Dalton. Trans., 1929.","DOI":"10.1039\/b601840h"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1039\/C5DT03919C","article-title":"Metal-based drugs that break the rules","volume":"45","author":"Allardyce","year":"2016","journal-title":"Dalton. Trans."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejmech.2017.04.007","article-title":"Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives","volume":"142","author":"Rilak","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccr.2014.08.002","article-title":"Noble metals in medicine: Latest advances","volume":"284","author":"Medici","year":"2015","journal-title":"Coord. Chem. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ccr.2006.11.017","article-title":"Using coordination chemistry to design new medicines","volume":"251","author":"Ronconi","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1039\/B707077M","article-title":"Bioorganometallic chemistry--from teaching paradigms to medicinal applications","volume":"38","author":"Hartinger","year":"2009","journal-title":"Chem. Soc. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yan, Y.K., Melchart, M., Habtemariam, A., and Sadler, P.J. (2005). Organometallic chemistry, biology and medicine: Ruthenium arene anticancer complexes. Chem. Commun., 4764.","DOI":"10.1039\/b508531b"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/ejic.200600723","article-title":"Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy","volume":"2006","author":"Dyson","year":"2006","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-010-1293-1","article-title":"Ruthenium-based chemotherapeutics: Are they ready for prime time?","volume":"66","author":"Antonarakis","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1039\/B916860P","article-title":"Arene ruthenium complexes as anticancer agents","volume":"39","year":"2010","journal-title":"Dalton Trans."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1039\/b904071d","article-title":"Recent developments in ruthenium anticancer drugs","volume":"1","author":"Levina","year":"2009","journal-title":"Metallomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cbpa.2007.11.013","article-title":"New trends for metal complexes with anticancer activity","volume":"12","author":"Bruijnincx","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aoc.725","article-title":"Development of organometallic (organo-transition metal) pharmaceuticals","volume":"19","author":"Allardyce","year":"2005","journal-title":"Appl. Organomet. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","article-title":"KP1019, A New Redox-Active Anticancer Agent-Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients","volume":"5","author":"Hartinger","year":"2008","journal-title":"Chem. Biodivers."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/1568026043387421","article-title":"Ruthenium antimetastatic agents","volume":"4","author":"Alessio","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_24","unstructured":"van Eldik, R., and Hubbard, C.D. (2003). Advances in Inorganic Chemistry: Inorganic Reaction Mechanisms, Academic Press. [1st ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic Anticancer Compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","article-title":"Tracking antitumor metallodrugs: Promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds","volume":"8","author":"Morais","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ica.2012.09.026","article-title":"New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins","volume":"394","author":"Matos","year":"2013","journal-title":"Inorg. Chim. Acta"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jinorgbio.2016.12.008","article-title":"Studies on the mechanism of action of antitumor bis(aminophenolate) ruthenium(III) complexes","volume":"168","author":"Matos","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1021\/acs.jmedchem.7b01689","article-title":"Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?","volume":"61","author":"Thota","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1021\/acs.inorgchem.8b01270","article-title":"RuII (p-cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in vivo","volume":"57","author":"Robalo","year":"2018","journal-title":"Inorg. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1389557043487484","article-title":"The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes","volume":"4","author":"Beraldo","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejmech.2006.05.012","article-title":"Nitrofurylsemicarbazone rhenium and ruthenium complexes as anti-trypanosomal agents","volume":"41","author":"Otero","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0020-1693(02)01277-X","article-title":"Synthesis and characterization of new ruthenium complexes with active ligands against Chagas\u2019 disease","volume":"344","author":"Otero","year":"2003","journal-title":"Inorg. Chim. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/AAC.15.2.157","article-title":"Activity of antitumor drugs against African trypanosomes","volume":"15","author":"Kinnamon","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ica.2012.05.028","article-title":"Perspectives on what ruthenium-based compounds could offer in the development of potential antiparasitic drugs","volume":"393","author":"Gambino","year":"2012","journal-title":"Inorg. Chim. Acta"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1039\/C5DT04011F","article-title":"Copper(I) complexes with phosphine derived from sparfloxacin. Part II: A first insight into the cytotoxic action mode","volume":"45","author":"Komarnicka","year":"2016","journal-title":"Dalton. Trans."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejmech.2004.01.002","article-title":"Ruthenium (II) nitrofurylsemicarbazone complexes: New DNA binding agents","volume":"39","author":"Cabrera","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/med.10039","article-title":"In silico prediction of drug-binding strengths to human serum albumin","volume":"23","author":"Colmenarejo","year":"2003","journal-title":"Med. Res. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.2174\/092986710793213742","article-title":"Transport of therapeutic vanadium and ruthenium complexes by blood plasma components","volume":"17","author":"Pessoa","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/15216540500404093","article-title":"The extraordinary ligand binding properties of human serum albumin","volume":"57","author":"Fasano","year":"2005","journal-title":"IUBMB Life (International Union Biochem. Mol. Biol. Life)"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural Basis of the Drug-binding Specificity of Human Serum Albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1002\/chem.200801032","article-title":"In vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands","volume":"14","author":"Berger","year":"2008","journal-title":"Chem. A Eur. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc100070g","article-title":"Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects","volume":"21","author":"Maeda","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40005-017-0370-4","article-title":"Nanomedicines: Current status and future perspectives in aspect of drug delivery and pharmacokinetics","volume":"48","author":"Choi","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1039\/c3dt00028a","article-title":"Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: Cytotoxic activity and human serum albumin binding mechanism","volume":"42","author":"Demoro","year":"2013","journal-title":"Dalton. Trans."},{"key":"ref_47","first-page":"151","article-title":"Circular dichroism in coordination compounds","volume":"97","author":"Correia","year":"2009","journal-title":"J. Argentine Chem. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Alessio, E., Messori, L., Alessio, E., and Messori, L. (2019). NAMI-A and KP1019\/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules, 24.","DOI":"10.3390\/molecules24101995"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2016.08.001","article-title":"Interactions between proteins and Ru compounds of medicinal interest: A structural perspective","volume":"326","author":"Merlino","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lakowicz, J.R. (2006). Principles of Fluorescence Spectroscopy, Springer.","DOI":"10.1007\/978-0-387-46312-4"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00775-014-1110-0","article-title":"Insights into the mechanisms underlying the antiproliferative potential of a Co(II) coordination compound bearing 1,10-phenanthroline-5,6-dione: DNA and protein interaction studies","volume":"19","author":"Silva","year":"2014","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0009-3084(02)00180-9","article-title":"Interaction of peptides with binary phospholipid membranes: Application of fluorescence methodologies","volume":"122","author":"Loura","year":"2003","journal-title":"Chem. Phys. Lipids"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Valeur, B., and Berberan-Santos, M.N. (2001). Molecular Fluorescence: Principles and Applications, Wiley-VCH Verlag GMBh.","DOI":"10.1002\/3527600248"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jinorgbio.2012.04.014","article-title":"Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines","volume":"114","author":"Morais","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"D\u00f6m\u00f6t\u00f6r, O., and Enyedy, \u00c9.A. (2019). Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: A comparative study. J. Biol. Inorg. Chem.","DOI":"10.1007\/s00775-019-01683-0"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cphc.201000742","article-title":"Exploring the Drug-Binding Site Sudlow I of Human Serum Albumin: The Role of Water and Trp214 in Molecular Recognition and Ligand Binding","volume":"12","year":"2011","journal-title":"ChemPhysChem"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Evans, I.P., Spencer, A., and Wilkinson, G. (1973). Dichlorotetrakis(dimethyl sulphoxide)ruthenium(II) and its use as a source material for some new ruthenium(II) complexes. J. Chem. Soc. Dalton. Trans., 204.","DOI":"10.1039\/dt9730000204"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jakusch, T., Hollender, D., Enyedy, \u00c9.A., Gonz\u00e1lez, C.S., Montes-Bay\u00f3n, M., Sanz-Medel, A., Costa Pessoa, J., Tomaz, I., and Kiss, T. (2009). Biospeciation of various antidiabetic VIVO compounds in serum. Dalton. Trans., 2428.","DOI":"10.1039\/b817748a"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/ed070p425","article-title":"Ribonuclease T1 and alcohol dehydrogenase fluorescence quenching by acrylamide: A laboratory experiment for undergraduate students","volume":"70","author":"Coutinho","year":"1993","journal-title":"J. Chem. Educ."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","article-title":"Cell Sensitivity Assays: The MTT Assay","volume":"731","author":"Kaspers","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm0104217","article-title":"Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals","volume":"45","author":"Maurer","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jinorgbio.2012.06.016","article-title":"[RuII(\u03b75-C\u2085H\u2085)(bipy)(PPh\u2083)]+, a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin","volume":"117","author":"Tomaz","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jinorgbio.2009.10.005","article-title":"In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model","volume":"104","author":"Bergamo","year":"2010","journal-title":"J. Inorg. Biochem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110727","DOI":"10.1016\/j.jinorgbio.2019.110727","article-title":"Exploring the cytotoxic activity of new phenanthroline salicylaldimine Zn(II) complexes","volume":"198","author":"Matos","year":"2019","journal-title":"J. Inorg. Biochem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/16\/2861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:09:12Z","timestamp":1760188152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/16\/2861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":64,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["molecules24162861"],"URL":"https:\/\/doi.org\/10.3390\/molecules24162861","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2019,8,7]]}}}